These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

59 related articles for article (PubMed ID: 3879662)

  • 1. [Analysis of effector T lymphocyte subpopulations necessary to mediate semisyngeneic tumor rejection in mice].
    Keyaki A
    Nihon Geka Hokan; 1985 Nov; 54(6):460-77. PubMed ID: 3879662
    [No Abstract]   [Full Text] [Related]  

  • 2. Expression of multiple unique rejection antigens on murine leukemia BALB/c RLmale symbol1 and the role of dominant Akt antigen for tumor escape.
    Matsuo M; Wada H; Honda S; Tawara I; Uenaka A; Kanematsu T; Nakayama E
    J Immunol; 1999 Jun; 162(11):6420-5. PubMed ID: 10352255
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor induction by immunologically activated murine leukemia virus: cellular immunity early in the graft-vs-host reaction.
    Ruddle NH; Armstrong MY; Richards FF
    J Immunol; 1974 Feb; 112(2):706-15. PubMed ID: 4149884
    [No Abstract]   [Full Text] [Related]  

  • 4. [Effect of the Friend leukemia virus on lymphocyte subpopulations in the mouse].
    Jezzi T; Premrov MG; Del Gobbo V; Garaci E
    Ann Ist Super Sanita; 1982; 18(3):513-5. PubMed ID: 6230037
    [No Abstract]   [Full Text] [Related]  

  • 5. Maturation of cytotoxic effector cells at the site of allograft rejection.
    Ascher NL; Chen S; Hoffman R; Simmons RL
    Transplant Proc; 1981 Mar; 13(1 Pt 2):1105-7. PubMed ID: 6973856
    [No Abstract]   [Full Text] [Related]  

  • 6. Studies of H-2 restriction in cell-mediated cytotoxicity and transplantation immunity to Leukemia-associated antigens.
    Ting CC; Law LW
    J Immunol; 1977 Apr; 118(4):1259-64. PubMed ID: 191534
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Secondary cytotoxic tumor immune response induced in vitro.
    Röllinghoff M
    J Immunol; 1974 May; 112(5):1718-25. PubMed ID: 4544796
    [No Abstract]   [Full Text] [Related]  

  • 8. T-lymphocyte-mediated cytolysis: contribution of intracellular components to target cell susceptibility.
    Berke G; Fishelson Z
    Transplant Proc; 1977 Mar; 9(1):671-4. PubMed ID: 301311
    [No Abstract]   [Full Text] [Related]  

  • 9. Temperature control of lymphocyte-mediated cytotoxicity in vitro.
    Berke G; Sullivan KA
    Transplant Proc; 1973 Mar; 5(1):421-3. PubMed ID: 4695950
    [No Abstract]   [Full Text] [Related]  

  • 10. Suppression of secondary cellular immunity to a tumor allograft by cyclophosphamide and 1,3-bis(2-chloroethyl)-1-nitrosourea.
    Einstein AB; Fass L; Fefer A
    Cancer Res; 1975 Mar; 35(3):492-6. PubMed ID: 1078784
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cell-mediated anti-tumor response in the RLmale 1 system. I. T nature, H-2Dd involvement and antigenic specificity of the effector cells.
    Duprez V; Gomard E; Levy JP
    Eur J Immunol; 1978 Sep; 8(9):650-5. PubMed ID: 81780
    [No Abstract]   [Full Text] [Related]  

  • 12. Relationships among differentiated T-cell subpopulations. V. T-cell dependent mechanism of xenograft rejection and its radioresistant nature.
    Terasaka R; Nomoto K; Himeno K
    Immunology; 1979 Dec; 38(4):773-9. PubMed ID: 316419
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of alloimmunization-induced T lymphocytes reactive against AKR leukemia in vitro and correlation with graft-vs-leukemia activity in vivo.
    Truitt RL; Shih CY; Lefever AV; Tempelis LD; Andreani M; Bortin MM
    J Immunol; 1983 Oct; 131(4):2050-8. PubMed ID: 6194224
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vivo studies of the role of cytotoxic T cells in tumor allograft immunity.
    Freedman LR; Cerottini JC; Brunner KT
    J Immunol; 1972 Dec; 109(6):1371-8. PubMed ID: 4538966
    [No Abstract]   [Full Text] [Related]  

  • 15. Effect of graft-versus-host disease on anti-tumor immunity.
    Schreiber KL; Forman J
    J Immunol; 1990 Mar; 144(5):2018-26. PubMed ID: 1968493
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immune response to an allogeneic progressively growing solid tumor.
    Eggers AE
    Cancer Res; 1976 Jun; 36(6):2085-9. PubMed ID: 773534
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immune response of BALB/c X DBA/2F1 mice to a tumor allograft during pyran copolymer-induced tumor enhancement.
    Schultz RM; Woods WA; Mohr SJ; Chirigos MA
    Cancer Res; 1976 May; 36(5):1641-6. PubMed ID: 1268825
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Abrogation of graft-vs.-leukemia activity after depletion of CD3+ T cells in a murine model of MHC-matched peripheral blood progenitor cell transplantation (PBPCT).
    Uharek L; Glass B; Zeis M; Dreger P; Steinmann J; Löffler H; Schmitz N
    Exp Hematol; 1998 Feb; 26(2):93-9. PubMed ID: 9472798
    [TBL] [Abstract][Full Text] [Related]  

  • 19. H-40, an antigen controlled by an Igh-linked gene and recognized by cytotoxic T lymphocytes. II. Recognition of H-40 as a tumor antigen in leukemic animals.
    Henderson LA; Ciavarra R; Riblet R; Forman J
    J Immunol; 1984 Nov; 133(5):2778-85. PubMed ID: 6434638
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enhancement of a tumor allograft in BALB/c x DBA/2 F1 mice by pyran copolymer.
    Mohr SJ; Chirigos MA; Fuhrman F; Smith G
    Cancer Res; 1976 Apr; 36(4):1315-9. PubMed ID: 1260757
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.